Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis

Hypertension Research

Volumn 27, Issue 12, 2004, Pages 971-978

  Asai, Masaki ^a   Monkawa, Toshiaki ^a   Marumo, Takeshi ^b   Fukuda, Seiichi ^a   Tsuji, Mihoko ^a   Yoshino, Jun ^a   Kawachi, Hiroshi ^c   Shimizu, Fujio ^c   Hayashi, Matsuhiko ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin converting enzyme inhibitor; Anti Thy 1 nephritis; Glomerulonephritis; Spironolactone

Indexed keywords

CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID RECEPTOR; NEPHRIN; SPIRONOLACTONE; THYMOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; GLOMERULONEPHRITIS; KIDNEY CORTEX; KIDNEY FIBROSIS; MALE; MONOTHERAPY; NONHUMAN; PROTEINURIA; RAT; RAT STRAIN; RENAL PROTECTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, THY-1; BLOOD PRESSURE; CILAZAPRIL; DRUG THERAPY, COMBINATION; FIBROSIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; KIDNEY; MALE; MEMBRANE PROTEINS; PROTEINURIA; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 20144369870     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.971     Document Type: Article

References (26)

1. Campbell R, Sangalli F, Perticucci E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094-1103.
2. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study investigators N Engl J Med 1999; 341: 709-717.
3. Pitt B, Williams G, Remme W, et al: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79-87.
4. Delyani JA, Rocha R, Cook CS, et al: Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001; 19: 185-200.
5. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
6. Rogerson FM, Brennan FE, Fuller PJ: Mineralocorticoid receptor binding, structure and function. Mol Cell Endocrinol 2004; 217: 203-212.
7. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
8. Brown NJ, Nakamura S, Ma L, et al: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227.
9. Feria I, Pichardo I, Juarez P, et al: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.
10. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677-688.
11. Kawachi H, Orikasa M, Matsui K, et al: Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen. Clin Exp Immunol 1992; 88: 399-404.
12. Cheng QL, Orikasa M, Morioka T, et al: Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Clin Exp Immunol 1995; 102: 181-185.
13. Nakaya H, Sasamura H, Kitamura Y, et al: Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens Res 1999; 22: 303-312.
14. Nakamura T, Obata J, Kimura H, et al: Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999; 55: 877-889.
15. Mezzano SA, Aros CA, Droguett A, et al: Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int 2003; 64 (Suppl): S39-S45.
16. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S: Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994; 45 1637-1647.
17. Kawachi H, Koike H, Kurihara H, et al: Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000; 57: 1949-1961.
18. Topham PS, Kawachi H, Haydar SA, et al: Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 1999; 104: 1559-1566.
19. Ikezumi Y, Kanno K, Koike H, et al: FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int 2002; 61: 1339-1350.
20. Shinosaki T, Miyai I, Nomura Y, Kobayashi T, Sunagawa N, Kurihara H: Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron 2002; 91 719-729.
21. Kobayashi S, Moriya H, Nakabayashi I, Nishiyama J, Fukuda T: Angiotensin II and IGF-I may interact to regulate tubulointerstitial cell kinetics and phenotypic changes in hypertensive rats. Hypertens Res 2002; 25: 257-269.
22. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
23. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
24. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
25. Arima S, Kohagura K, Xu HL, et al: Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
26. Wang PR, Masuda Y, Kitamura H, Yamanaka N: Tubulointerstitial injury of Thy-1 nephritis in uninephrectomized stroke-prone spontaneously hypertensive rats. J Nippon Med Sch 2001; 68: 301-309.